EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

David J Allsup iD, David A Cairns iD, E Faye Samy, Lelia Duley, Adrian Bloor, Abraham Varghese, David Meads, Bryony Dawkins, Sean Girvan, Dena R Howard, Anna Hockaday, Julia M Brown und 12 weitere

British Journal of Haematology · 2026-05 · 208 (5) · 1596-1607

DOI: 10.1111/bjh.70416 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, online erschienen am 30.03.2026. Verfasst von David J Allsup und 23 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, UK. Hauptthemen laut MEDLINE: Quality of Life, Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceuticals, Pharmacyclics, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL). This report presents the secondary end‐point of health‐related quality of life (HR‐QoL). FLAIR was a phase 3, open‐label, randomised trial across 101 hospitals. Eligible patients were aged 18–75 years, World Health Organization performance status (PS) ≤2, requiring treatment; those with >20% 17p deletion were excluded. IR was administered for up to 6 years and FCR for six cycles. Participants completed European Organisation for Research and Treatment of Cancer Quality of Life C30 Questionnaire (EORTC‐QLQ‐C30), QLQ CLL Module (QLQ‐CLL16), three‐level EQ‐5D (EQ‐5D‐3L) and EQ5D visual analogue (EQ‐VAS) at baseline and follow‐up. Function and symptom trajectories were analysed using repeated‐measures multilevel regression. 84.4% of participants completed baseline questionnaires and subsequent compliance was 67.6%–83.5%. Median age was 63 years; most participants were white and male. HR‐QoL trajectories were similar. FCR recipients had worse scores at end of treatment but recovered thereafter. By 48 months, more FCR‐treated participants showed meaningful improvements in several scales. Statistically significant differences ( p < 0.05) favoured IR for physical, role and social function; emotional function favoured FCR. Diarrhoea was more common with IR; fatigue and dyspnoea were more common with FCR, though differences did not exceed minimally important thresholds. Overall, scales were comparable between treatment groups, indicating that continuous IR does not compromise HR‐QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsHumansRituximabCyclophosphamideMiddle AgedMalePiperidinesAgedAdenineFemaleAdultVidarabinePatient Reported Outcome MeasuresYoung AdultAdolescent

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorchemoimmunotherapychronic lymphocytic leukaemiahealth‐related quality of liferandomised controlled trial

Substanzen

RituximabCyclophosphamidePiperidinesAdenineibrutinibfludarabineVidarabine

Autor:innen und Institutionen

  • Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, UK.
  • Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Frontier Science Scotland, Kingussie, UK.
  • CLL Support, Chippenham, UK.
  • The Christie Hospital NHS Foundation Trust, Manchester, UK.
  • Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK.

ORCID-Profile: David J Allsup, David A Cairns, Piers E M Patten, Andrew Rawstron, Talha Munir

Förderung

  • Janssen Pharmaceuticals
  • Pharmacyclics
  • AbbVie
  • Core Clinical Trials Unit Infrastructure
  • Cancer Research UK
  • Janssen Pharmaceutica

Zitieren

APA

Allsup, D. J., Cairns, D. A., Samy, E. F., Duley, L., Bloor, A., Varghese, A., Meads, D., Dawkins, B., Girvan, S., Howard, D. R., Hockaday, A., Brown, J. M., Jackson, S., Greatorex, N., Templeton, P., Tupper, M., Phillips, D., Yaqub, S., Mortimer, D., …, & Munir, T. (2026). Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab. British Journal of Haematology, 208(5), 1596-1607. https://doi.org/10.1111/bjh.70416

Vancouver

Allsup DJ, Cairns DA, Samy EF, Duley L, Bloor A, Varghese A, et al. Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab. British Journal of Haematology. 2026;208(5):1596-1607. doi:10.1111/bjh.70416

BibTeX
@article{Allsup2026,
  author = {Allsup, David J and Cairns, David A and Samy, E Faye and Duley, Lelia and Bloor, Adrian and Varghese, Abraham and Meads, David and Dawkins, Bryony and Girvan, Sean and Howard, Dena R and Hockaday, Anna and Brown, Julia M and Jackson, Sharon and Greatorex, Natasha and Templeton, Phoebe and Tupper, Michael and Phillips, David and Yaqub, Sonam and Mortimer, Di and Stones, David and Patten, Piers E M and Rawstron, Andrew and Hillmen, Peter and Munir, Talha},
  title = {Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {5},
  pages = {1596--1607},
  doi = {10.1111/bjh.70416}
}
Kostenlos starten →